<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04923516</url>
  </required_header>
  <id_info>
    <org_study_id>2021-A00566-35</org_study_id>
    <nct_id>NCT04923516</nct_id>
  </id_info>
  <brief_title>Prevalence of Acute Hepatic Porphyria</brief_title>
  <acronym>PHA</acronym>
  <official_title>Prevalence of Acute Hepatic Porphyria in Population With Suggestive Clinical Picture</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Association pour la Recherche en Medecine Interne</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Association pour la Recherche en Medecine Interne</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine the proportion of patients suffering from acute hepatic porphyria (AHP) from&#xD;
      different hospital departments and referred to an internist referent for a suggestive&#xD;
      clinical picture with a first negative etiological assessment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this context, this study aims to assess the prevalence of PHA in a population of patients&#xD;
      with a suggestive clinical picture. A better knowledge of the pathology will make it possible&#xD;
      to better guide patients and prevent them from diagnostic wandering fraught with physical and&#xD;
      psychological consequences.&#xD;
&#xD;
      This is an observational, ambispective, transversal, multicenter study carried out in France.&#xD;
      The goal is to recruit a cohort that will reflect current practice. 500 patients will be&#xD;
      recruted.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 2021</start_date>
  <completion_date type="Anticipated">April 2022</completion_date>
  <primary_completion_date type="Anticipated">April 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Binary criterion corresponding to the diagnosis of acute hepatic porphyria (acute hepatic porphyria + / acute hepatic porphyria -) via physiological parameter.</measure>
    <time_frame>1 day</time_frame>
    <description>The diagnosis of acute hepatic porphyria is based on urine testing of the neurotoxic precursors of haem: Delta-aminolevulinic acid and Porphobilinogen. A patient will be considered to have acute hepatic porphyria (acute hepatic porphyria +) if:&#xD;
Delta-aminolevulinic acid ≥ 3 µmol / mol Cr And or&#xD;
Porphobilinogen ≥ 1 µmol / mol Cr Otherwise, the patient will be considered to be acute hepatic porphyria free (acute hepatic porphyria -).</description>
  </primary_outcome>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Acute Hepatic Porphyria</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Dosage of Delta-aminolevulinic acid and Porphobilinogen</intervention_name>
    <description>Results of dosages of Delta-aminolevulinic acid and Porphobilinogen which are performed in accordance with the current practice will be recorded</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The target population is made up of patients presenting signs suggestive of acute hepatic&#xD;
        porphyria or recently diagnosed, from consultations with gastroenterologists, emergency&#xD;
        physicians, neurologists, gynecologists, internists or other specialties, referred to an&#xD;
        acute hepatic porphyria referent internist participating in the study, within the framework&#xD;
        of of the etiological exploration of their clinical picture.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Man or woman aged 18 to 60;&#xD;
&#xD;
          -  Presenting severe abdominal pain, afebrile and diffuse over several days, evolving for&#xD;
             less than 5 years;&#xD;
&#xD;
          -  With at least one of the following symptoms:&#xD;
&#xD;
               -  Peripheral neurological symptoms: decreased driving force and pain in the limbs&#xD;
                  (roots of the thighs), etc. ;&#xD;
&#xD;
               -  Central neurological symptoms: psychiatric (depression, anxiety, insomnia),&#xD;
                  disturbances of consciousness, etc. ;&#xD;
&#xD;
               -  Autonomous neurological symptoms: tachycardia, nausea, vomiting, constipation,&#xD;
                  etc.&#xD;
&#xD;
          -  With a first negative etiological assessment requested by an emergency physician,&#xD;
             gastroenterologist, gynecologist, neurologist, internist or another specialty, or with&#xD;
             a diagnosis of acute hepatic porphyria less than 6 months;&#xD;
&#xD;
          -  Patient able to understand the information related to the study and having indicated&#xD;
             his non-objection to the collection of data concerning him;&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient with a diagnosis of acute hepatic porphyria for more than 6 months;&#xD;
&#xD;
          -  Patient unfit to participate in the study, due to cognitive or linguistic&#xD;
             difficulties;&#xD;
&#xD;
          -  Protected patient (under legal protection, or deprived of liberty by judicial or&#xD;
             administrative decision).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Patrice CACOUB, MD</last_name>
    <phone>01 42 17 80 27</phone>
    <email>patrice.cacoub@aphp.fr</email>
  </overall_contact>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 8, 2021</study_first_submitted>
  <study_first_submitted_qc>June 8, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 11, 2021</study_first_posted>
  <last_update_submitted>June 11, 2021</last_update_submitted>
  <last_update_submitted_qc>June 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Porphyrias, Hepatic</mesh_term>
    <mesh_term>Coproporphyria, Hereditary</mesh_term>
    <mesh_term>Porphyria, Erythropoietic</mesh_term>
    <mesh_term>Porphyrias</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aminolevulinic Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

